Neoprobe Corporation, a diversified developer of innovative biomedical surgical oncology products, today announced that its gamma radiation detection system product line, which includes the neo2000® and neoprobe® GDS systems, was featured in a peer reviewed publication characterizing the emergence of the use of radioactive "seeds" to assist in the surgical excision of non-palpable breast lesions.
More...